Swiss national radio interviews Mattias Ivarsson about Inositec’s therapeutic approach to treat Clostridium difficile infection (in French).
6th November 2014
Categories
Most Recent
- Inositec Appoints Serial Entrepreneur and Cardiologist Michael H. Davidson to Board of Directors
- Inositec Granted US Composition of Matter Patent for Cardiovascular Calcification Inhibitor INS-3001
- Preclinical work on calcium oxalate inhibitors for renal indications published
- Inositec’s INS-3001 Significantly Reduces Cardiovascular Calcification in Proof-of-Concept Studies Published in Nature Communications
- Discovery work on Clostridium difficile toxin inhibitors published